Lucent Diagnostics and Tempus AI have partnered to integrate blood-based Alzheimer’s biomarker testing into clinical workflows, aiming to expand access and improve detection accuracy for neurologists.
Presentations will feature results from the NHS-Galleri and PATHFINDER 2 studies involving more than 174,000 participants.
Blue Shield of California will cover Plus Therapeutics’ CNSide CSF assay for metastatic CNS cancers starting April 2026, expanding total covered lives to 81 million, according to the company.
Foundation Medicine will acquire SAGA Diagnostics’ Pathlight MRD platform, expanding its cancer monitoring portfolio. The $595 million deal is expected to close by Q3 2026, with integration supporting treatment selection and recurrence monitoring.
Read More
TCM Biotech has received FDA Breakthrough Device Designation for CatCHimera, a liquid biopsy platform for monitoring minimal residual disease in hepatocellular carcinoma using HBV–host genome integration biomarkers.
Read More
Labcorp has launched nationwide testing with Agilent’s FDA-approved PD-L1 IHC 22C3 pharmDx, enabling identification of patients with platinum-resistant ovarian cancer eligible for pembrolizumab immunotherapy.
Read More
The agreement aims to increase the availability of therapeutic drug monitoring tests for psychiatry and oncology patients using existing laboratory equipment.
Read More
The seed funding will support the commercialization of a platform designed to generate biomarker insights from pathology images without laboratory staining.
Read More
The $100 million deal brings an ultra-fast system for respiratory viruses to QuidelOrtho’s point-of-care portfolio.
Read More
The FDA has cleared Labcorp’s rapid fentanyl urine test, which detects norfentanyl and delivers results in 10 minutes for use in CLIA-certified labs, according to the company’s press release.
Read More
Presentations at AACR 2026 will showcase fragmentomics-based technology for detecting therapeutic markers and providing prognostic insight.
Read More
The system offers faster run times and reduced sample consumption for the analysis of viral vectors, protein aggregates, and advanced materials.
Read More
The collaboration focuses on creating sensitive assays for a common genetic risk factor to guide drug development and clinical trials.
Read More
The collaboration will use multi-omic platforms and AI-driven analytics to identify disease patterns and improve patient stratification within the PRECISE-SG100K study.
Read More
The collaboration aims to create an innovation pipeline for specialized pediatric tests across oncology, metabolic disease, and autoimmune conditions.
Read More
A multicenter trial published in Clinical Chemistry reports Vitestro’s autonomous phlebotomy system achieved a 94.5% first-stick success rate, with low hemolysis and adverse event rates, in routine clinical settings.
Read More
The collaboration focuses on implementing a liquid handling platform to streamline end-to-end laboratory processes and protocol development.
Read More
The high-throughput host-response assay provides results in approximately 20 minutes to help guide treatment decisions and antimicrobial stewardship.
Read More